CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 503 enrolled
Drug / intervention
Questionnaireother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05171270
NCT05171270N/ACompleted

How Does PsAID Implementation Affect Treatment Intensification and Patient Satisfaction in PsA

University of Oxford·observational·Posted Dec 28, 2021·Updated Sep 25, 2024

In Brief

An observational study evaluating Questionnaire for Psoriatic Arthritis. Completed, enrolled 503 participants across 21 sites in 5 countries.

Detailed Summary

Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves trial and error to find the right medication for the right person. Very little is known about the decisions made to increase treatment in individual patients. Previous research in rheumatoid arthritis found that clinical measures of disease activity, patient reported outcomes and characteristics of the treating doctor all influenced the decision to change therapy in routine practice. This investigators particularly want to establish whether routine use of the psoriatic arthritis impact of disease (PsAID-12) questionnaire in the clinic setting can enable a better understanding of the impact of PsA on each individual, improve physician-patient communication and lead to appropriate interventions. The PsAID-12 questionnaire is a relatively new European developed questionnaire measuring patient impact across 12 different domains in PsA. This study will use routine implementation of the PsAID-12 questionnaire and see if this is related to treatment decisions and patient satisfaction. The investigators will also examine other factors that may influence treatment decisions including patient characteristics, physician characteristics, disease activity and quality of patient-physician interactions.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesFrance, Germany, Italy, Spain, United Kingdom
CollaboratorsAmgen

Timeline

N/ACompletedFinished
20222023202420252026
First PostedDec 28, 2021
Enrollment StartJul 12, 2021
Primary CompletionMar 22, 2022
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 4.5 years ago

Interventions

Questionnaireother

PsAID questionnaire